Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02625-w ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Ayumu Mitsuyoshi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, …. Hauptthemen laut MEDLINE: Neutrophils, Breast Neoplasms, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
PURPOSE: The aim of this study was to elucidate the clinical significance of peripheral blood biomarkers, including absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR), at the end of treatment (EOT) with CDK4/6 inhibitors abemaciclib and palbociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. METHODS: We included 67 patients treated with fulvestrant plus abemaciclib or palbociclib. Overall survival (OS) since the EOT with CDK/4/6 inhibitors was compared in relation to the levels of ALC and NLR. The cut-off values of ALC and NLR were set at 1000/μL and 3, respectively. RESULTS: Patients with a high ALC at EOT showed significantly longer OS than those with a low ALC (p = 0.0358). Moreover, patients with a low NLR at EOT showed significantly longer OS than those with a high NLR at EOT (p = 0.0044). Looking at the changes of ALC and NLR between baseline and the EOT, patients with a high ALC both at baseline and at the EOT showed significantly longer OS than others (p = 0.0201). Similarly, patients with a low NLR both at baseline and at the EOT showed significantly longer OS after EOT than others (p = 0.0136). Multivariable analysis revealed that the NLR at EOT (low vs. high) and changes in NLR (low at baseline to low at EOT vs. others) were significant and independent prognostic factors for OS after EOT (p = 0.0337, p = 0.0039, respectively). CONCLUSION: NLR at EOT with CDK4/6 inhibitors is a significant and independent prognostic marker for patients with ER-positive HER2-negative advanced breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan.
- Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan. ma-nagahashi@hyo-med.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Mitsuyoshi, A., Nagahashi, M., Kanaoka, H., Oshiro, A., Togashi, Y., Hattori, A., Tsuchida, J., Higuchi, T., Nishimukai, A., Murase, K., Takatsuka, Y., & Miyoshi, Y. (2024). Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02625-w
Vancouver
Mitsuyoshi A, Nagahashi M, Kanaoka H, Oshiro A, Togashi Y, Hattori A, et al. Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02625-w
BibTeX
@article{Mitsuyoshi2024,
author = {Mitsuyoshi, Ayumu and Nagahashi, Masayuki and Kanaoka, Haruka and Oshiro, Aoi and Togashi, Yusa and Hattori, Akira and Tsuchida, Junko and Higuchi, Tomoko and Nishimukai, Arisa and Murase, Keiko and Takatsuka, Yuichi and Miyoshi, Yasuo},
title = {Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02625-w}
}
EUVIMED